Oral therapy wins approval in Europe for already-treated metastatic PDAC
Drug to be used on its own to treat most common type of pancreatic cancer
Written by |
Rasonque has been approved in the European Union as a treatment for pancreatic cancer that has spread beyond the organ. (Image from iStock)
The oral drug Rasonque (daraxonrasib) — a non-chemotherapy treatment — has been cleared in the European Union for treating certain adults with pancreatic adenocarcinoma (PDAC), the most common form of pancreatic cancer.
The approval by the European Commission, which applies in all EU member states plus Iceland, Norway, and Liechtenstein, specifically covers the use of Rasonque in patients with metastatic disease — meaning the cancer has spread outside the pancreas — who have received at least one prior line of systemic therapy. The treatment can be used by patients with or without an identified RAS tumor mutation, a genetic change that drives continued cell growth.
The green light covers Rasonque’s use as monotherapy, meaning on its own. Therapy maker Revolution Medicines said in a company press release that it’s working with healthcare systems across the EU to provide access to the newly approved treatment to people with PDAC.
“[The] European Commission approval of Rasonque represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families,” said Mark A. Goldsmith, MD, PhD, chairman and CEO of Revolution.
The European approval comes just a few months after the drug was approved for a similar indication in the U.S.
“With Rasonque now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients. We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of Rasonque to patients who may benefit from it,” Goldsmith said.
Rasonque nearly doubled survival time in key trial
Approvals in both the U.S. and the EU were based mainly on data from RASolute 302 (NCT06625320), a Phase 3 clinical trial that tested Rasonque against standard chemotherapy in 500 adults with previously treated metastatic PDAC. Rasonque nearly doubled overall median survival time (13.2 months vs. 6.7 months), the results showed.
According to Rasonque’s U.S. prescribing information, the most common side effects of this oral treatment include rash, diarrhea, nausea, fatigue, vomiting, abdominal pain, and swelling. Inflammation of the lining of the mouth, known as stomatitis, and reduced appetite were also common, as was hemorrhage, or heavy bleeding.
The drug blocks the activity of RAS proteins, a group of signaling proteins that commonly contribute to abnormal cell growth in PDAC. With Rasonque approved for previously treated PDAC, Revolutions is also developing the therapy as a potential first-line treatment.
An ongoing Phase 3 trial, RASolute 303 (NCT07491445), is enrolling adults with newly diagnosed PDAC at sites across Europe, Asia, Australia, Canada, and Brazil. Participants will be randomly assigned to receive Rasonque only, Rasonque plus standard chemotherapy, or chemotherapy only. The main goal is to determine whether Rasonque slows disease progression and improves survival.
Thomas Seufferlein, medical director of Ulm University Hospital in Germany, called the approval “an important advance for patients with this aggressive and difficult-to-treat” cancer.
“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond … chemotherapy, underscoring the urgent need for new therapeutic approaches,” Seufferlein said.
Leave a comment
Fill in the required fields to post. Your email address will not be published.